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Abstract:  
Background: Hepatitis E virus (HEV) infection is a major public health concern in developing 
countries. HEV transmission occurs primarily by the oral-fecal route. This could progress to an 
acute self-limiting disease. Severe cases are more common among pregnant and immune-
compromised patients, leading to a high mortality rate in these populations. 
Objectives: This study aimed to evaluate whether the rate of seroprevalence of IgG anti-HEV 
and IgM anti-HEV are associated with sociodemographic variables, clinical history, personal 
hygiene ,and other related risk factors among the general population in West Bank ,Palestine . 
Method: This seroepidemiological cross-sectional study was conducted from October 2016 to 
March 2017 include 432 participants from all governorates of West Bank, Palestine. Participants 
answered the questionnaire regarding the sociodemographic, clinical and personal hygiene 
characteristic. Blood samples were tested for IgG and IgM to HEV by an enzyme linked 
immunosorbent assay (ELISA). All serum samples positive for total anti-HEV were also assayed 
for IgM anti-HEV by ELISA. 
Results: The overall seroprevalevce of anti-HEV was 3.7% (16/432). There was a significant 
association between anti-HEV seropositivity and levels of education.  Anti-HEV reactivity 
among subjects with less than Tawjihi level (93.75% 15 out of 16) was higher than other group 
with high education level. Other associated factor with anti- HEV seropositivity, place of distract 
(P< 0.0107), the incidence rates of HEV seropositivity subjects were the highest in Ariha and 
Salfit (2/ 10= 0.20), but most cases of HEV seropositive subjects came from Al-Khalil 
populations 31.3% (5/16). Although participants aged ≥40 years had the highest prevalence, but 
there was no significant difference between the age groups. However, no significant relationship 
was observed between positive anti-HEV and other sociodemographic variables, travel, clinical 
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history (such as surgical procedures, dental procedures, and contact with hepatitis patients), and 
personal hygiene (such as type of sewage systems and history of animals contact).  
Conclusion: Although this study revealed low seroprevalence of HEV infection in the study 
population, the results showed that the HEV virus is circulating among the West Bank 
population of Palestine. This study points out the need for further studies to define the clinical 
and epidemiological importance of HEV infection and to identify additional risk factors involved 
in the epidemiology and pathogenesis of HEV infection. 
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Introduction: 
 
Hepatitis E is a viral hepatitis caused by infection with hepatitis E virus (HEV). HEV is one of 
five human hepatitis viruses: A, B, C, D and E. HEV is a non-enveloped, positive sense, single 
stranded RNA (Fujiwara et al., 2014) as shown in figure1. It has been classified into the genus 
Hepevirus and has been reassigned into the Hepeviridae family (Aggarawal et al., 2012). 
Infection with hepatitis E virus was first documentedin 1955 in New Delhi, India during an 
outbreak (Aggarawal et al., 2011).  
HEV is primarily transmitted through feces-contaminated water and eating uncooked or 
undercooked meat of HEV-infected animals. Person-to-person transmission occurs, but rarely via 
fecal-oral routes (Khuroo et al., 2015 and Vitral et al., 2014).  
In developing countries, HEV is responsible for acute hepatitis outbreaks due to contamination 
of drinking water; however patients clear the virus rapidly. In developed countries, HEV is now 
considered as an emerging disease due to the increased number of autochthonous; chronic state 
HEV infection (Khuroo et al., 2015). Its severity varies from asymptomatic or self-limited, to 
fulminate. Mortality associated with hepatitis E infection is typically low, except when those 
infected are pregnant or immune-compromised (Teshale et al., 2010). 
Therapy should be predominantly preventive. Practicing proper personal hygiene is essential, as 
well as avoiding drinking contaminated water and using good sanitation systems. There is 
currently no Food and Drug Administration (FDA)-approved vaccine for hepatitis E infection 
(Aggarawal et al., 2011).  
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Although there are no reports from the Palestinian Ministry of Health (MOH), indicating that 
there is a prevalence of hepatitis E in Palestine. This study was the first study done in West 
Bank, Palestine to determine the prevalence and risk factors of Hepatitis E infections among 
Palestinians in the West Bank.  
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Chapter One: 
_____________________________________________________________________________________ 
Literature Review 
1.1. Virus Biology: 
 Hepatitis E is a viral hepatitis caused by the Hepatitis E virus (HEV), also known as enterically 
transmitted, non-A, non-B virus (Trinta et al., 2001 and Aggrawal et al., 2000). HEV is a 
member of the Genus Hepevirus and the Family Hepeviridae. As shown in figure 1 it is a 
positive-sense, single-stranded, non-enveloped RNA of approximately 7.5 kilobase (kb) 
(Verghese et al., and Yoon et al., 2014). 
 
 
Figure 1: Hepatitis E Virus structure (Aggarwal et al., 2011). 
 
1.2. Life cycle of HEV: 
 
The knowledge on the HEV life cycle is limited, mainly because of the inefficiency of current 
cell culture models for HEV propagation (Schemerer et al., 2016).Cellular receptors and entry 
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modes of HEV into the host cell are not known, but it is known that HEV requires heparin 
sulfate proteoglycans to attach and infected target cells. The viral particles concentrated on the 
surface of hepatocytes are internalized after binding a specific receptor. The virus then sheds its 
coat to release genomic RNA that is translated into nonstructural proteins inside the cytoplasm. 
RNA-dependent RNA polymerases replicate the positive-sense genomic RNA into negative-
sense transcripts; the latter then act as templates for the synthesis of a 2.2-kb subgenomic RNA, 
as well as full-length, positive sense transcripts. The positive-sense subgenomic RNA is 
translated into open reading frame (ORF) 2 and ORF3 proteins. The ORF2 protein packages the 
genomic RNA to assemble new virions, while the ORF3 protein may optimize the host cell 
environment for viral replication. The ORF3 protein is also associated with endomembranes, or 
plasma membranes, and may aid in viral egress (Khuroo et al., 2015) as shown in figure 2.  
 
Figure 2 :Proposed life cycle of HEV.Step a: HEV attaches to the cell surface via HSPGs, HSC70 or other 
putative attachment receptor(s) and then enters the cell via unknown specific cellular receptor.Step b:. The virion 
then uncoats and releases the positive-sense genomic RNA into the cytoplasm of the cell. Step c: The positive-sense 
genomic viralRNA serves as the template to translate the ORF1 nonstructural polyprotein in the cytoplasm. Step d: 
The viral RdRp synthesizes an intermediate, replicative negative-sense RNA from the positive-sense genomic RNA 
that step e: serves as the template for the production of positive-sense, progeny viral genomes. Step f: The 
ORF2and ORF3 proteins are translated from the sub genomic, positive-stranded RNA, and step g: the ORF2 capsid 
protein packages the genomic viral RNA and assemblesnew virions. Step h: The nascent virions are transported to 
the cell membrane, and step i: the nascent virions are released from the infected cells. (Cao et al., 2102).  
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1.3. Route of Transmission of Hepatitis E infection: 
HEV can be transmitted horizontally by the oral-fecal route through fecal contamination of water 
supplies in regions with poor sanitation, food-borne transmission from ingestion of products 
derived from infected animals, and transfusion of infected blood products (although rare). 
Hepatitis E can also be transmitted vertically, through mother-fetus transmission. Finally, it is 
also known that there is also a possibility of zoonotic virus transmission (Banks et al., 2010, 
Colson et al., 2007 and Krain et al., 2014).  
 
1.4. Typical Immune Responses to Hepatitis E Virus: 
 
HEV is known as non-cytopathic. The liver injury during hepatitis E infections can be mediated 
by the host immune response. The direct cytopathic effect of the HEV has been difficult to study 
because the virus has not been cultured efficiently in-vitro. Both cellular and humoral mediated 
immunity play an important role in the pathogenesis of HEV infection. Cellular immune 
responses, both innate and adaptive immunity, are very important for viral clearance (Srivastava 
et al., 2007). Natural killer cells (NK), natural killer-like T cells (NKT), dendritic cells, and 
antigen-specific MHC class1-restricted CD8
+
cells are involved in the lysing of virus-infected 
cells by producing IFN-γ (Szomolanyi-Tsuda et al., 2002). NK and NKT cells are the major 
source of IFN-γ in the liver (Rehermann et al., 2003).  
Patient suffering from HEV typically exhibit an increase in the total level of CD4
+
, IFN-γ, and 
IL-1β. However, usually there is no increase in the levels of CD8
+
, IL-2 and TNF-α. That 
suggests CD4
+
 IFN γ secreting cells neither belong to T-helper cell type 1 nor to type 2 that are 
involved in the pathogenesis of HEV. Increased production of IFN-γ and the absence of CD8
+
 
cell response lead to nonspecific innate immunity, NK and NKT cells play a significant role in 
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pathogenesis of HEV (Srivastava et al., 2007). The humoral immunity by the aid of antibodies 
plays a crucial role in neutralizing the virus (Schofield et al., 2000). However, both IgM and IgG 
appear concomitantly with the development of the jaundice.  Persistence of virus and exact role 
in protection against HEV reinfection are still unclear (Khuroo et al., 1993). 
 
1.5. Epidemiology of Hepatitis E Virus: 
 
 According to World Health Organization (WHO), HEV causes around 20 million cases every 
year, with over 3 million of those being acute infection. It is also known that about 70000 deaths 
occur worldwide per year; related to hepatic failure. An estimated one-third of the world’s 
population has been infected with HEV (WHO, 2014; Holla et al., 2013, and Rein et al., 2012). 
HEV is responsible for more than 50% of acute viral hepatitis in adults in endemic areas, and 1% 
in non-endemic areas. Due to these high numbers and the harmfulness of this infection, HEV 
represents an important public health concern in many developing countries, especially in those 
with high-risk populations (Arora et al., 1996 and Perez-Gracia et al., 2014). 
There have been large numbers of epidemiological studies in different parts of the world, 
showing the wide variation in HEV seroprevalence patterns (see table 1).  It has been found that 
anti-HEV antibodies are present in persons living in all geographical areas. Though the HEV 
seroprevalence rates are higher among developing countries, high prevalence rates are often 
reported from South Asia, Egypt in the Middle East, and the Far East, except Japan. Low rates 
are often found in developed countries, such as Europe and the Americas (Mushahwar et al., 
2008, Aggarwal et al., 2011 and Trinta et al., 2001).  
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                Table 1: Prevalence of anti-HEV in the general populations  
 Anti-HEV% Reference 
Asia 
Iran 
Korea 
Bangladesh 
 
10% 
5.9% 
22.5% 
 
(Behzadifar et al., 2016) 
(Yoon et al., 2014) 
(Labrique et al., 2009) 
Europe 
Franca 
Spain 
Italy 
 
16.6% 
1.1% 
3.9% 
 
(Mansuy et al., 2008) 
(Fogeda et al., 2012) 
(Scotto et al., 2014) 
Africa 
South Africa 
Nigeria 
 
15.3% 
43% 
 
(Tucker et al., 1996) 
(Ola et al., 2012) 
Americans 
USA 
Canada 
 
21% 
3% 
 
(Kuniholm et al., 2009) 
(Minuk et al. , 2007) 
 
 
These differences between studies could be related to ecological, environmental, and/or cultural 
variations, as well as differences in the hygiene condition, education levels, access of safe water 
sources, and sanitary sewage systems. Other factors associated with anti-HEV seropositivity are 
animal contact, occupational activity, and method of washing fruit and vegetables. 
1.6. General Epidemiology: 
HEV has two distinct epidemiological profiles as quite different conditions: 
1- As large outbreaks and epidemics cases of hepatitis E in areas of endemicity, infected 
with genotype 1 in Asia and Africa, genotype 2 in Mexico and Africa, resulting in high 
morbidity among pregnant women and young children (Traore et al., 2012 and Bayhan et 
al., 2016).  
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2- As isolated clinical cases, known as sporadic cases where no epidemic has been reported 
in industrialized areas infected with genotype 3 (Wang et al., 1999).  
 
1.7. Seroprevalence of HEV in Blood Donors: 
Providing safe blood is a major concern of any blood bank in the world. It has been reported in 
many countries that blood donors are potentially able to cause transfusion-associated hepatitis E 
(Boxall et al., 2006; Tamura et al., 2007, and Matsubayashi et al., 2008). Its true frequency, 
however, is underestimated because testing of blood donors is infrequent and due to the 
sometimes asymptomatic nature of the infection. Asymptomatic HEV infection makes nucleic 
acid tests (NAT) is a molecular technique used to detect a particular pathogen (virus or 
bacterium) in a specimen of blood or other tissue or body fluid. It does so by detecting and 
amplifying the RNA or DNA of the pathogen which makes extra copies of its nucleic acids to 
detect and prevent transfusion of contaminated blood donations. In Japan, HEV infection by 
blood transfusion has been reported in Hokkaido, which is regarded as a region with increasing 
danger of HEV infection. Therefore, and unfortunately, it is the only place in the world where 
donor blood is screened for HEV RNA (Vollmer et al., 2016). 
 
1.8. Complicated Infection, Immune Response and Outcomes: 
 
1.8.1. HEV Infection in Pregnancy: 
 
HEV infection is usually associated with mild and self-limited diseases that can lead to fulminant 
hepatic failure (FHF). This severe form of disease is particularly common among pregnant 
women with HEV infection with a mortality rate varying from 20-25% during the second and 
third trimester of pregnancy. It has been reported to be associated with the mortality rate of 80% 
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in HEV-induced fulminant hepatic failure cases in this trimester. Moreover, HEV in pregnancy is 
associated with spontaneous abortion, still births, low birth weight, and preterm delivery 
(Mamum et al., 2009, Sepanlou et al., 2010 and Begum et al., 2010).  
HEV has both a high incidence and severe course in pregnant women in some regions of HEV 
endemic areas, such as India (Patra et al., 2007). In other HEV endemic areas, such as Egypt, it 
has been shown to have a benign course with little or no morbidity. These differences could be 
the result of early childhood HEV exposures, producing immunity. These differences can also be 
explained by stating that the predominant HEV genotype in Egypt could be less virulent than 
those in Asia (Stoszek et al., 2006).  
The high mortality rate in pregnancy has been thought to be secondary to the associated 
hormonal and steroid hormone, estrogen, progesterone, and human chorionic gonadotropin 
(HCG), increase during pregnancy and consequent immunological changes. These 
immunological changes include down regulation of p 65 component of NK with a predominant 
Th2 bias in the T cell response along with host susceptibility factors mediated by Human 
Leukocyte Antigen (HLA) expression. These steroid hormones may promote viral replication. 
These hormones also have a direct inhibition on hepatic cells, which may predispose to hepatic 
failure when exposed to infectious agents. Jilani et al. found that HEV infected pregnant women 
with FHF have lower CD4 counts and higher CD8 counts. They also observed that the level of 
steroid hormones were significantly higher than HEV-negative pregnant women.   
Moreover, pregnancy is characterized by a state of maternal immune tolerance toward the fetus. 
T cell activity is reduced, leading to a decrease of cytokines production. Th2 responses increase 
and Th1 and immunological changes in the placenta down regulate antigen presentation. Finally, 
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recent studies showed higher viral load in HEV-infected pregnant women than in non-pregnant 
women (Navaneethan et al., 2008).  
Some studies showed the percentage of seroprevalence of HEV infection among pregnant 
women: in Ghana 28.66% (Adjei et al., 2009), Goban 14.1% (Caron et al., 2008), Egypt 84.3% 
(Stoszek et al., 2006), India 60% (Oncu et al., 2006), 5.7% in rural pregnant women in Durango 
in Mexico (Alvarado-Espuivel et al., 2014) and 7.36% in Gorgon, North East of Caspian Sea 
(Tabarrae et al. 2011).  
 
1.8.2. Chronic  HEV Infection: 
Hepatitis E infection is an emerging clinical threat in developed countries, especially among the 
immunocompromised and individuals with underlying chronic liver disease, exhibiting the 
zoonotic pathway. To date, there are no known cases of chronic Hepatitis E in developing areas. 
However, most cases of Hepatitis E with progression to chronic hepatitis and chronic liver illness 
are being reported among HEV genotype 3 cases acquired in the developed areas. These chronic 
cases are almost exclusively among those who are on immunosuppressive treatment for solid 
organ transplant (Hoofnagle et al., 2012 and Kamar et al., 2014). Autochthonous HEV infection 
has an important cause of hepatitis among solid organ transplant recipients’ progression to 
chronic HEV infection, defined as HEV viremia persisting for more than six month (Kamar et 
al., 2011).  
Globally, chronic HEV infection has emerged as an important cause of morbidity among solid 
organ transplant recipients. Many studies in Germany, France, and the Netherland showed that 6- 
8 % of all unknown causes of liver dysfunction among recipient patients may be due to HEV 
infection, with more than 60% of these progressing to chronic liver hepatitis (Kamer et al., 2008, 
Haagsma et al., 2008, Pas et al., 2012; and Moal et al., 2013). This type of infection was also 
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associated with an increased risk for graft rejection, particularly among kidney transplant 
recipients (Sue et al., 2016).  
Immune dysfunction was observed in cirrhotic patients, who presented decreased innate immune 
system activity with a reduction in NK cell activity (Chuang et al., 1991). Innate immunity also 
suppressed in advanced stages of liver fibrosis (Jeong et al., 2011). Moreover, HEV on its own 
can contribute to a down regulation of immune activity. Proteins encoded by HEV ORF 3 gene 
might reduce the host inflammatory response to create viral replication (Chandra et al., 2008). 
Secretion of immunosuppressive α1- microglobulin was increased in HEV ORF 3-protein, 
expressing cells potentially resulting in a protection of virus infected cells (Surjit et al., 2006).  
Increasing the risk of acute hepatitis E that progresses the chronicity has relation with the  
importance of immune response against infection that  protects the host cell all patients were 
immunocompromised and progressed to chronic hepatitis have significantly CD3 and CD4  
lower counts. This finding highlights the importance of T-cell mediated immunity for pathogen 
clearance.  
 
1.9. Diagnosis of Hepatitis E Infection: 
The incubation period after exposure to the HEV ranges from 15-60 days, with a mean of 40 
days. Immediately prior to the onset of clinical symptoms, HEV can be detected in the 
bloodstream for 1-2 weeks, and is shed in stool at 3-4 weeks before the elevation of 
aminotransferases enzymes. At the onset of clinical symptoms, HEV virus is lost from the blood 
stream, but continues to be shed in stool (Kamar et al., 2014).  
HEV infection can be diagnosed by testing serum aminotransferases, alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST), bilirubinemia, variable degree of rise in serum 
12 
 
billirubin (mostly conjugated); and a mild increase in serum alkaline phosphates. These are 
sensitive, but not specific indicators for liver injury. Specific diagnosis of Hepatitis E is based on 
serological assays for HEV antibodies. Anti-HEV IgM and IgG titers continue to increase in the 
asymptomatic phase (Figure3). The anti-HEV IgM titer peaks the symptomatic phase and 
declines after to baseline values with 3-6 months of symptomatic illness. The anti-HEV IgG 
titers remain detectable for some years. In endemic areas, detection of IgM suggests acute 
infection, whereas IgG indicates past infection. In non-endemic areas, IgG has also been used for 
the diagnosis of acute or recent infection. No diagnostic assays for HEV have yet been approved 
by the FDA (Aggarwal et al., 2011).  
 
 
 
 
.    
                               Figure 3: Clinical, biochemical and serological profile of  
                                               HEV infection (Khuroo et al., 2015).  
  
 
Cases of Hepatitis E infection are not clinically distinguishable from other forms of acute viral 
hepatitis. Diagnosis of Hepatitis E virus infection is therefore based on the detection of specific 
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antibodies, virus in the blood stream. Enzyme linked immune-sorbent assay and western blot are 
used to detect anti-HEV IgM and IgG in serum. There are other assays: such as reverse 
transcriptase polymerase chain reaction (rt-PCR), to detect the HEV RNA in serum or stool, and 
immune-flouoresent antibody blocking assay to detect antibody to HEV antigen in the serum, 
and liver biopsies. Because of viremia and viral shedding, these assays may lack sensitivities.  
 
1.10. Technical Issues Would Influence Anti-HEV Testing: 
Currently commercially available serological assays are designed to detect anti-HEV Abs in 
human serum or plasma, based on their recombinant HEV proteins or synthetic peptides from 
ORF 2 and/or ORF 3 of HEV genotype 1 and 2. There may be a lower sensitivity for detection of 
infections with the genotype 3 in developed countries. Various reports indicate that commercial 
assays sometimes fail to detect specific anti-HEV genotype 3, and, thus, the numbers of 
autochthonous HEV infection in developed countries have been underestimated (Obriadina et al., 
2002).  
Most of these assays use recombinant polypeptides derived from the C and N terminal of ORF 2, 
or the C terminal of ORF 3. N and C terminal polypeptides from ORF 2 demonstrated greater 
abilities and were found to be more sensitive to detecting anti-HEV Abs than did those from 
ORF 3. This can be explained by the fact that anti-HEV against N and/ or C terminal 
polypeptides of ORF 2 appeared sooner than those against polypeptides ORF 3; thus, the N and 
C terminal polypeptides of ORF 2 may provide epitopes which are highly reactive with sera of 
acute HEV infection, while the C terminal polypeptides of ORF 3 may contain epitopes which 
are reactive with early convalescent phase sera, or from the later period of the acute phase (Ma et 
al., 2009). However, ORF 2-expressed proteins are believed to be more sensitive in detecting 
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anti-HEV IgM and IgG. In particular, the C terminal end of the ORf 2 region was found to 
contain a highly conserved conformational epitope and to be suitable for the specific and 
sensitive detection of anti-HEV Abs in ELISA assays (Chen et al., 2005). 
 
1.11. Prevention HEV Infection: 
 The risk of infection and transmission can be reduced by ways such as good sanitation and 
through the availability of clean drinking water. The risk of infection can be reduced by 
establishing proper hygienic practices, such as hand washing with safe water, avoiding drinking 
water of unknown purity, avoiding eating raw or undercooked meat and fruits or vegetables that 
are not peeled or that are prepared by people living in or travelling in highly endemic area. The 
virus is resistant to heating at 56 °C for one hour. However, it is susceptible to boiling and frying 
for 5 minutes and to chlorination. Immunoglobulin is not effective in preventing HEV infections 
(Khuroo et al., 2015).  
 
1.12. Objectives: 
Main objective: The purpose of the study was to evaluate the prevalence of HEV infection and 
the risk factors among Palestinians in West Bank, Palestine.  
Specific objective: 
1- Determine the demographic and geographic distribution of HEV. 
2 -Examine the presence of anti-HEV IgG and IgM in study using ELISA.  
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Chapter  Two: 
____________________________________________________________________________________ 
Materials and Methods: 
This chapter outlines the research methodology used.  It starts by explaining  the research design 
and methods used, which include the study population and its eligibility criteria, sample size, the 
sampling technique used, recruitment process, the method of data collection used, data analysis 
methods, the validity and reliability of the research instruments, and ethical considerations. 
2.1. Research Design and Study Population: 
The study used a descriptive cross-sectional research design. The study population consisted of 
consenting individuals attending the primary health care centers of the Ministry of Health in 
West Bank, Palestine. These centers were selected for convenience because patients attending 
these centers usually reside within the same district where the center is located and visit the 
center for medical consultations, and maternal and child health care. Since there were no data on 
the prevalence of HEV in West Bank, Palestine, we calculated a sample size based on prevalence 
50% (requiring the largest sample size) and with a precision of 5%. The minimum required 
sample size needed was 400 and 432 samples were tested. The tested samples were randomly 
selected to avoid any bias. 
2.2. Eligibility Criteria  
Individuals with positive results for hepatitis B and hepatitis C antibodies were excluded from 
the study to prevent an underestimation of the prevalence of anti-HEV seropositivity in the 
general population.  Immunocompromized patients were also excluded.  
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2.3. Questionnaire: 
A baseline questionnaire was applied to study participants to obtain behavioral characteristics, 
eating habits, contact with animals, blood transfusion, surgical and hospitalization history, and 
demographic, clinical, and socioeconomic status (SES) information which included level of 
education, income and occupation. The development of a formal questionnaire ensured that 
similar data were collected from all participants and it also ensured objectivity during the data 
collection process. (See appendix A).   
2.4. Specimen Collection, Transporting, and Preservation: 
A total of 5 ml blood was collected from each subject into labeled sterile plain tube. Each blood 
sample was allowed to clot and the serum was harvested into a sterile tube. The serum was 
separated by centrifugation at 3500 rpm for 5 minutes. The serum samples were stored at -20 °C 
until use.   
2.5. Serological Assays: 
All serum samples were tested for total antibodies for HEV, IgM and IgG, by using the 
commercial Fortress HEV-Abs enzyme linked immunosorbent assay from MBS New S.R.L, 
Opera Company in Milano, Italy. All the serum samples that gave positive results from the 
previous assay were tested for HEV-IgM enzyme linked immunosorbent assay. Both assays 
utilize proprietary recombinant antigens, which is highly conserved among different HEV 
strains, to detect the presence of specific antibodies, including IgM and IgG against HEV.  
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2.5.1. BEM  HEV-Ab  ELISA Assay: 
Principle of the assay: 
1- HEV Total Abs ELISA: 
This HEV-Ab ELISA kit uses microwell strips precoated with recombinant HEV antigens 
derived from conservative regions of ORF-2 of the native virus. In case of presence of HEV-Ab 
in the sample, the pre-coated antigens will be bound to the antibody during the first incubation 
step. After washing to remove unbound sample, second recombinant HEV antigen conjugated to 
Horseradish peroxides (HRP) is added into the wells. During the second incubation step, this 
antigen will bind to the second variable domain of the HEV Abs if they have been captured by 
HEV-antigen during the first incubation step. The unbound HRP-conjugate is removed during 
washing and chromogen solutions containing Tetramethylbenzidine (TMB) is added into the 
wells. In presence of the Ag-Ab-Ag (HRP), the colorless chromogens are hydrolyzed by the 
bound HRP-conjugate to a blue colored product. The amount of color intensity is proportional to 
the amount of Ab captured in the wells. Wells containing samples negative for HEV remain 
colorless.  
2- HEV-IgM ELISA: 
Principle of the Assay:In two-step incubation, solid phase ELISA assay, in which microwell 
strips are pre-coated with HEV-specific immuno-dominant synthetic antigens, directed to human 
immunoglobulin M proteins (anti-μ chain). During the first incubation step, any IgM-class 
antibodies will be captured in the wells. After washing out all ofthe other substances of the 
sample, IgG-class antibodies were blocked directly into the well by a neutralizing reagent. 
During the second incubation, the anti-hIgM antibody labeled with peroxidase (HRP) will 
specifically react only with HEV IgM antibodies. After washing to remove the unbound HRP-
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conjugate, chromogen solutions were added into the wells. In presence of (HEV-Ag) - (HEV-
IgM) - (anti-hIgM-HRP) immunocomplex, the colorless chromogens are hydrolyzed by the 
bound HRP-conjugate to a blue-colored product. The blue color turns yellow after stopping the 
reaction with0.3 M sulfuric acid. 
ELISA Procedure for Total Anti-HEV and Anti-HEV IgM: 
For total abs, 100 µL of Diluted specimens were added into each well expect the blank. 100 µL 
of positive control, negative control, and specimen were added into their respective wells except 
the blank. After 60 minutes of incubation at 37 °C, the wells were washed with diluted wash 
buffer (Dilute 1 to 25 with distilled water), 100 µL HRP-conjugate was added to all the wells, 
except blank, as second Abs and incubated for 30 minutes at 37 °C, washed with diluted wash 
buffer. 100 µL of chromogen/substrate to all the wells, including the blank and incubated for 15 
minutes at 25 °C, blue color in the positive control and positive sample for HEV were produced 
by the enzymatic reaction. Then 100 µL of stop solution (0.3 M H2SO4) was added into each 
well, intensive yellow color was developed in the positive control and positive sample for HEV-
Ab. Color development was measured at 450nm by using ELISA Reader (RT- 2100C Microplate 
Reader).while HEV- IgM assay procedure was the same, but 50 µL of neutralizing reagent was 
added in each well, except the blank and in the wells used for controls.     
2.6. Statistical Analysis: 
A database was set up using the EPI INFO software version 7. The participant demographic and 
socioeconomic status including gender, age, educational level, occupation, and region were 
derived from their study questionnaire. For comparison of categorical variables between groups 
were assessed by using the Chi test and fisher’s exact test. The level of significance adopted for 
all tests was 5% (p<0.05).  
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2.7. Ethical consideration: 
The study was granted ethical permission from the Ministry of Health, as shown in appendix B. 
Written informed consent was also obtained from all of the participants of this study, either by 
consenting for themselves or through parental consent, which is shown in appendix C. 
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Chapter  Three:  
__________________________________________________________________  
Results: 
Characteristics of study subjects and prevalence characteristics are described in this chapter. In 
addition, the findings regarding infectious risk factors for HEV infection are demonstrated.  
3.1. Characteristics of the participants: 
General participant’s characteristics are summarized in Table 2. In total there were 432 subjects, 
213 males and 219 females. The subjects were classified into five age groups: 0-9, 10-19, 20-29, 
30-39, and over 40 years. 81 subjects were between 0 and 9 years old, while 77 subjects were 
between 10 and 19 years old, 84 subjects were between 20-29 years old, 84 subjects were 
between 30-39 years old, and 106 subjects were older than 40 years old. Among the participants, 
9.26%  lived in Jenin, 2.31% in Salfit, 25.23% in Al-Khalil, 4.63% in Qalqilia, 2.31% in Tubas, 
15.51% in Nablus, 14.12% in Ramallah, 2.31% in Ariha, 12.5% in Al-Quds, and 7.41% in 
Bethlehem. Other results of the questionnaire are shown in Table 2.  
3.2. HEV infection prevalence: 
Overall, the prevalence of anti-HEV total antibodies was 3.7% (16/432). All the 16 subjects with 
positive results for anti-HEV total Abs were negative results for anti-HEV IgM Abs, so the 
prevalence of anti-HEV IgG Abs among a general population in West Bank, Palestine was 3.7%.  
The sociodemographic status (SES), clinical and personal hygiene characteristics of the subject 
enrolled according to seropositivity for anti-HEV IgG are shown in Table 2, 3 and 4.  
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HEV seroprevalence was higher among males compared to females, but this was not statistically 
significant. Anti-HEV was distributed among all age groups. Although people aged ≥ 40 years 
had the highest prevalence, but there was no significant difference between the age groups.  
However, with regard to place of district, anti- HEV IgG positivity was significantly associated 
with place of district (P= 0.0107), the incidence rates of HEV seropositivity subjects were the 
highest in Ariha and Salfit ( 2/ 10 = 0.20), but  most cases of  HEV seropositive subjects came 
from Al-Khalil populations  31.3% (5/16). 
A similar pattern of a positive association of anti-HEV reactivity with education was found 
among study subjects (Table 2).  Anti-HEV reactivity among subjects with less than Tawjihi 
level (93.75% 15 out of 16) was higher than other group with high education level. There was a 
significant statistical difference between them (P< 0.05).  
In our study, no higher seroprevalence was found among people working in potentially risk 
professions such as health professional, then among those with less potentially risky jobs, such as 
clerical workers and students.  
As shown in Table 3, there was no statistically significant association between anti- HEV IgG 
seropositivity and the presence of sewage system, source of water and toilette were taken into 
consideration (P> 0.05).  
Of the clinical characteristics studies that were summarized in Table 4, seropositivity to HEV 
were not associated with blood transfusion, dental, surgical procedure, travel aboard and HBV/ 
HCV contacts.   
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Table 2: Sociodemographic characteristics of 432 subjects in the West Bank, Palestine, 
distributed according to seropositivity for anti-Hepatitis virus E (anti-HEV IgG) antibodies.  
Characteristic Anti-HEV 
positive N  
Anti-HEV 
negative N 
Total  P -Value  
Gender 
Male  
Female  
Total  
 
11 
5 
16 
 
202 
214 
416 
 
213 
219 
432 
P= 0.1 NS  
Age 
0-9 
10-19 
20-29 
30-39 
≥40 
Total  
 
4 
4 
1 
1 
6 
16 
 
77 
73 
83 
83 
100 
416 
 
81 
77 
84 
84 
106 
432 
 
P= 0.12  NS  
Place of District  
Jenin 
Alkhalil 
Salfit 
Tulkarem 
Qalqilia 
Tubas 
Nablus 
Ramallah 
Ariha 
Alquds 
Bethlehem 
Total  
 
 
2 
5 
1 
0 
1 
2 
3 
0 
2 
0 
0 
16 
 
38 
104 
9 
19 
19 
8 
64 
61 
8 
54 
32 
416 
 
40 
109 
10 
19 
20 
10 
67 
61 
10 
54 
32 
432 
P= 0.0178  Sig  
Education level  
<Tawjihi 
>Tawjihi 
Total  
 
15 
1 
16 
 
288 
128 
416 
 
303 
129 
432 
P= 0.04 Sig  
Income  
<= 1450 
>1450 
Total  
 
3 
13 
16 
 
49 
367 
416 
 
52 
380 
432 
P=0.42  NS 
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Occupation 
Student 
Housewife 
Worker 
Clerical worker 
HealthProfessional 
Teacher 
None 
Total  
 
3 
4 
4 
1 
0 
0 
4 
16 
 
 
96 
77 
88 
55 
27 
25 
48 
416 
 
99 
81 
92 
56 
27 
25 
52 
432 
 
P= 0.48 NS  
N: Number of subjects; NS: not significant; sig: significant.  
 
Table 3: Personal hygiene characteristics of 432 subjects in the West Bank, Palestine, distributed 
according to seropositivity for anti-Hepatitis virus E (anti-HEV IgG) antibodies.  
Characteristic Anti-HEV 
positive N  
Anti-HEV 
negative N 
Total  P- Value  
Drinking water  
Well 
Bottle 
Pipe in house 
Total  
 
 
3 
0 
13 
16 
 
35 
10 
367 
412 
 
38 
10 
380 
428 
P= 0.3137 NS  
Toilette type 
Flush 
Open pit 
Total  
 
 
10 
6 
16 
 
289 
127 
416 
 
299 
133 
432 
P= 0.58NS  
Toilette link 
Septic tank 
Sewage network 
Total  
 
 
10 
6 
16 
 
261 
155 
416 
 
271 
161 
432 
P= 1 NS  
Swimming  
Yes 
No 
Total  
 
4 
12 
16 
 
153 
263 
416 
 
157 
275 
432 
P= 0.43 NS  
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Animal contact 
Yes  
No   
Total  
 
10 
6 
16 
 
202 
214 
416 
 
212 
220 
432 
 
P= 0.3 NS  
N: Number of subjects; NS: not significant.  
Table 4: Clinical characteristics of 432 subjects in the West Bank, Palestine, distributed 
according to seropositivity for anti-Hepatitis virus E (anti-HEV IgG) antibodies.  
Characteristic Anti-HEV 
positive N  
Anti-HEV 
negative N 
Total  P- Value  
Surgery procedure  
Yes  
No 
Total  
 
7 
9 
16 
 
131 
285 
416 
 
138 
294 
432 
P=0.4 NS 
Dental procedure 
Yes  
No 
Total  
 
10 
6 
16 
 
278 
138 
416 
 
288 
144 
432 
P= 0.7 NS  
Blood transfusion 
Yes  
No 
Total  
 
0 
16 
16 
 
27 
389 
416 
 
27 
405 
432 
P= 0.61 NS  
HBV/ HCV contact 
Yes  
No 
Total  
 
1 
15 
16 
 
27 
389 
416 
 
28 
404 
432 
P= 0.6 NS  
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Travel aboard 
Yes  
No  
Total  
 
5 
11 
16  
 
166 
250 
416 
 
171 
261 
432 
P= 0.60 NS  
N: Number of subjects; NS: not significant.  
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Chapter Four:  
 
Discussion, Limitations and Conclusion: 
 
4.1 Discussion: 
Hepatitis E infection is a worldwide public health concern, which causes large out breaks of 
acute hepatitis in developing countries especially Asia, Middle East, and Africa and also 
sporadic cases of Hepatitis E in developed countries.  
It was not possible to identify the etiological agent in some cases of viral hepatitis and those 
cases were classified as non-A, non-B, and non-C hepatitis infection. Therefore, it is possible 
some of those cases might have been HEV infection (Bortoliero et al., 2006).  
For epidemiological purpose, subjects can be considered to approximate to the healthy general 
population. However, the age criteria for blood sampling and the elimination of samples found to 
be positive for hepatitis B and C infection could lead to an underestimation of the prevalence of 
anti-HEV seropositivity in the general population. 
This study of HEV seroprevalence in West Bank, Palestine found that 3.7% of those sampled 
were positive, compared to, 2.81% the seroprevalence in Jewish populations (Karetnyi et al., 
1995).  This low prevalence is probably due to generally good hygienic conditions and controlled 
potable water supply as compared with other region.  
The seroprevalence in other countries were 14.8% in Saudi Arabi (Abdelaal et al., 1998), 20% in 
United Arab Emirates (Kumar et al., 2001), 10.7% in Yemen (Bawazi et al., 2010) and 45.3% in 
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Egypt (Abdel-hady et al., 1989). These variations it can due to differences in the demographics 
of studied population, the size of the samples and the public health services situation. High rates 
of HEV infection were reported in Jordan, 30.9% (Obaidat et al., 2017), a country having a long 
border and exchange of population and livestock with Palestine. Jordan has been for many years 
the destination of immigrants coming from many countries, in the Gulf war, Jordan had a major 
role in it receiving soldiers from different parts of the world with ported high prevalence of HEV 
infection and with outbreaks. However, in Jordan the most frequent risk factors associated with 
increased anti-HEV seropositivity; eating camel’s meat and being exposed to animals.  
Several studies have been shown that seroprevalence of HEV in a population generally increases 
with age (Verhoef et al., 2012) which seems to be a risk factor for anti-HEV positivity 
(Kuniholm et al., 2009, Yoon et al., and Vitral., et al., 2014)). In this study, most cases of anti-
HEV seropositivity distributed among aged groups ≥ 40 years old, but without significant 
association between aged groups, and it most likely reflects cumulative lifetime contact 
frequency to HEV. Also there some studies were shown no significant difference was found 
between different age groups (Bortoliero et al., 2006).  
A high infection rate was found in high density district compared with standard density district. 
However, a large household constitute a risk factors, thus indicating a risk of person to person 
transmission. The key differences between inhabitants of densely-populated district are a 
generally lower economic status, with a lower level of education. As in this study, the incidence 
rates of HEV seropositivity subjects were the highest in Ariha and Salfit ( 2/ 10= 0.2), but  most 
cases of  HEV seropositive subjects came from Al-Khalil populations  31.3% (5/16) since  25% 
of the samples originates from this district. Contaminated water and possible zoonotic reservoirs 
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may play important role in the distribution of HEV seroprevalence among the general 
population.  
Some studies have shown that the rate of HEV seropositivity is significantly higher in males than 
females (Xue-feng et al., 2008 and Takahashi et al., 2010), although some studies had shown 
higher rates in females (El-Tras et al., 2013), and other study shown no significant difference 
between males and females (Verhoef et al., and Mohebbi et al., 2012). In this study, HEV 
seroprevalence was higher among males compared to females, but this was not statistically 
significant. 
In this study, other associated factors with anti-HEV seropositivity were levels of education. The 
results indicated that the rate of positive anti-HEV subjects increased with lower education levels 
(Oncu et al., 2006 and Mamani et al., 2015), it indicates the positive impact of education on 
sanitation and hygiene practice.  However, previous studies have indicated that there was no 
difference in anti-HEV sreoprevalence according to educational level (Eick et al., 2010 and 
Ataei et al., 2009).  
Sometimes, HEV infect human through direct contact with domestic or farm animals or 
contaminated water supplies. However, in this study there was no association between anti-HEV 
serpositivity and animals contact. The recognition of swine HEV infection in pigs in many 
countries of the world (Vitral et al., 2014) led to investigate a larger sample of pigs in Palestine, 
may act as reservoirs of HEV infection in Palestinian populations.  
Some facts must be considered when studying the prevalence of HEV infection: we do not know 
the lifetime of antibodies for HEV and the test available for the detection of HEV antibodies 
seem to differ in their sensitivity and specificity. For these reasons it is difficult to determine the 
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true prevalence of HEV infection among any population, especially in regions of low 
endemicity. 
4.2 Limitations:  
A low prevalence of anti-HEV among the general population might affect the assessment of the 
risk factors associated with seropositivity for anti-HEV. The biggest challenges was faced , 25% 
of the samples came from Aِl-Khalil and this can cause bias in the interpretation of the results, so  
the prevalence rate  was not used to explain the association between anti-HEV seropositivity and 
place of district. Instead of, the incidence rate was used for assessment to ensure that there is no 
bias in interpreting the results.  
4.3 Conclusion: 
Despite showing a low prevalence of HEV infection among general population in West Bank, 
Palestine, the results obtained in the present study demonstrate that HEV circulates in West 
Bank, Palestine. However, further studies are necessary to define the clinical and epidemiologic 
importance of the HEV infection in this area and to identify additional risk factors involved in 
the epidemiology and pathogenesis of HEV infection. The results of this study open the 
possibility of other routes of disease spreading different from that previously recognized ones 
such as fecal-oral contamination such as the possible role of animals in the transmission of HEV.  
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Appendix A: 
HEPATITIS QUESTIONNAIRE 
 
Demographic Data 
Patient Name  Date of onset of 
symptoms/sampling 
........./............./................ 
DOB ............../.............../.................... Sex Male                      Female 
Marital status Single                                     Married                       divorce  
Address City/town/camps................................ District............................................. 
Level of education,  Elementary school                       Middle school                      University 
Occupation .................................................................................................................................................... 
Income <14500;            1450-3000,                        3000-5000              >5000NIS 
Clinical history 
Have you ever had surgical procedure?  Yes                                                      No 
If the answer is yes, What type of surgical 
procedure did you do 
 
 
 
......................................................................................................................... 
Do you receive blood transfusion Yes                                                     No 
If the answer is yes, when and where ..................................................................................................................... 
Have you ever had dentist procedures? Yes                                                     No 
Have you ever had jaundice? Yes                                                     No 
Do you have HCV? Yes                                                     No 
Do you have HBV? Yes                                                     No 
Do you have a house hold contact with 
HBV and/or HCV 
Yes                                                     No 
Have you ever been abroad?  Yes                                                     No 
If yes, where? ..................................................................................................................... 
Personal hygiene: 
Toilette  in house                                                 in yard 
Type Flush,                    open pits,                            bucket, 
Linked to septic tank                      sewage system 
Drinking water source Well,           piped into house,           piped into yard,         spring,...... 
If not pipe lined,  Do you treat water before drinking?  Yes    No;        How: 
How often do you wash hands after 
defecation 
Every time                       some times 
How often do you wash hands before lunch Every time                                      some times 
Eat raw vegetables  Yes                                                     No 
Eat unpeeled fruits Yes                                                     No 
Swimming practice  Yes                                                     No 
Eating out side home Yes                                                     No 
If yes, where  
44 
 
Do you raise domestic animals?  Yes                                                     No 
 Yes, mention………. 
 No, have animals in vicinity                    Yes                          No 
Lab test results 
HEV Total Ab Positive                                         Negative 
HEV IgM Positive                                         Negative 
Appendix B: 
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و عىامم انمخاطرج انمفترضح مه خلال دراسح قطاعيح عرضيح تيه   )ه( معذل اوتشار انتهاب انكثذ انىتائي
  فهسطيه . ،عامح انسكان في انضفح انغرتيح 
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  .اعذاد : ألاء محمذ طانة اتى دعمىس
  . أتى حهى انمشرف : د. رسمي
 انمهخص
ىي مصدر قمق رئيسي لمصحة العامة في البمدان النامية . يعتبر مرض التياب الكبد  )ه(عدوى فيروس التياب الكبد الوبائي 
مرض وبائي يصيب الكبد و ينتج ىذا الالتياب عن طريق فيروس التياب الكبد ه ,ينتقل ىذا الفيروس الي  )ه(الفيروسي 
الانسان عن طريق الفم بواسطو المأكل و المشرب المموثيين . ولأن الفيروس يخرج من المصاب عن طريق برازه فعاده  تكون 
ىذا  .ف الصحي . وىذا يمكن أن يتقدم إلى مرض حادة ذاتي الحدسبب العدوى المباشرة ىي شرب المياة المموثة بمياه الصر 
الحالات الشديدة ىي أكثر شيوعا بين الحوامل والمرضى المناعين لمخطر،  .المرض عادة ما يكون معتدلا في عامة السكان
 مما يؤدي إلى ارتفاع معدل الوفيات في ىؤلاء السكان .
لأجسام المضاده التي تكونت في أجسام المصابين ضد ىذا لانتشار المصمي  دراسة لتحديد و تقييم معدلالتم أجراء ىذه 
شخص من كل مناطق الضفة الغربية في  432الفيروس في الضفة الغربية في فمسطين . بحيث أجريت ىذه الدراسة عمى 
ن الديموغرافيا الأجتماعية فمسطين , وتم توزيع استبيان عمى المشاركون , وكل مشارك أجاب عمى الأستبيان الموزع الذي يتضم
 شخص تم فحصيا لمكشف عن الأجسام المضادةا 432, النظافة الشخصية و السريرية . عينات الأمصال التي تم جمعيا من 
ىن طريق تياب الاستخدام تقنية الأليزا . فكل العينات التي وجدت ايجابية لوجود  )ه (لكمية التي تكونت ضد التياب الكبد
, أيضا فحص لمكشف عن الأجسام المضاده الحاده التي تكونت ضد )ه (دة الكمية ضد  فيروس الكبد الوبائي الأجسام المضا
% , حيث كان ىناك ارتباط كبير بين ايجابية تكون الأجسام 3.3ىذا الفيروس باستخدام تقنية الأليزا. فكان الأنتشار المصمي 
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التفاعمية بين الأجسام المضادة وىذا الفيروس خلال الأشخاص الايجابين المضادة ضد ىذا الفيروس مع مستوى التعميم , كانت 
دون مستوى التوجييي أعمى من المجموعة التي ليا مستوى تعميمي عالي . بالنسبة لمكان انتشار ىذا المرض الفيروسي 
)، إلا أن معظم 02.0= 01/2( ) أعهى فً أرٌحب وسهفٍثهالإنحهبة انكبدي انىببئً ( في مناطق الضفة الغربية , )ه( الوبائي
). عهى انزغم مه أن انمشبركٍه انذٌه 11/5٪ (3.13 مه انخهٍم  جبءت  )ه( حبلات الإصببة ببنفٍزوس انمصبة بفٍزوس
ومع ذلك لا يوجد  .عبمب كبن أعهى معدل اوحشبر، ونكه نم ٌكه هىبك فزق كبٍز بٍه انفئبت انعمزٌة 04 ≥جحزاوح أعمبرهم بٍه
علاقة كبيرة بين الأشخاص الذين كانو لدييم أجسام مضادة ضد ىذا الفيروس في أمصاليم و التغييرات الديموغرافية, 
الأجتماعية الأخرى مثل (الحالة الأجتماعية , السفر , و النظافة الشخصية) . بالرغم أن ىذه الدراسة كشفت انتشار مصمي 
في الأشخاص المشاركين, الأ أن النتائج بينت أن ىذا الفيروس منتشر بين سكان )ه (الكبد الوبائي  قميل لعدوى فيروس التياب
 الضفة الغربية في فسطين . 
ىمية السريرية و الوبائية ليذه العدوى لمتعرف عمى الأىذه الدراسة تشير الي الحاجة لمزيد من الدراسات الاضافية لتحديد 
الى ىذا المرض و ليا علاقة في عمم الأوبئة و طريقة تطور المرض لعدوى التياب الكبد العوامل أخرى اضافية تودي 
 . )ه (الفيروسي الوبائي
 
 
